The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy.
K. Pietzner
No relevant relationships to disclose
J. Sehouli
No relevant relationships to disclose
J. Atz
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
K. Dettmar
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
H. Martinius
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
R. Spannagl
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
D. Seimetz
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
P. Schroeder
Employment or Leadership Position - EUFETS GmbH
Other Remuneration - Fresenius Biotech
H. Lindhofer
Employment or Leadership Position - TRION Pharma
Stock Ownership - TRION Pharma
G. Oskay-Ă–zcelik
No relevant relationships to disclose
R. Chekerov
No relevant relationships to disclose
E. I. Braicu
No relevant relationships to disclose